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RNS vs Surgery Among Patients with Epilepsy in Eloquent Foci
• Both Surgical Resection and RNS reduce seizures compared to medical 
management alone. 
• Longitudinal prospective studies reveal the safety and relatively few adverse 
events associated with Neuropace.
• Certain populations may benefit from Neuropace over Surgical resection (those 
with seizure foci in eloquent corticies)
• Providers should be aware of options available for treatment of refractory 
seizures. 
LIMITATIONS
• No direct comparison between RNS and Surgical Resection 
• Differences in N, baseline seizure frequency, age of participants, and 
seizure foci location do not permit comparisons between studies of 
RNS and surgical resection. 
• Blinding was only achieved in Morell (2011) 
• Blinding reduces participant and research bias 
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Over 50 million people worldwide suffer from epilepsy. Up to 40% of cases are 
refractory to medical management. Historically, these patients were offered 
surgery to control symptoms at the risk of losing critical human functions such as 
language and motion. Neuropace Responsive Neurostimulation (RNS) is a 
minimally invasive novel device that detects and responds to seizure activity. 
(P) Among patients with refractory epilepsy with seizures involving eloquent 
corticies
(I) is RNS or 
(C) surgical resection 
(O) safer and more effective in reducing seizures. 
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Seizure Classification: 2017 International League Against Epilepsy
❖ Focal Onset: Originating in one hemisphere 
❖ Aware vs Impaired Awareness
❖ Motor vs nonmotor
❖ Generalized Onset: Originating in both hemispheres
❖ Motor vs nonmotor (absence)
❖ Unknown Onset
❖ Motor vs nonmotor
❖ Epilepsy: ≥2 unprovoked seizures more than 24 hours apart
Treatment Options
❖ Medical management: up to 40% of epilepsy cases are refractory to medical 
management with two or more medications
❖ Surgical Resection: Traditional standard of care for refractory epilepsy 
❖ RNS: Electrodes placed near seizure foci detect and respond to abnormal brain 
activity. Neuropace RNS is the only FDA approved device for refractory epilepsy.
Eloquent Foci
❖ Areas of the brain responsible for language, vision, sensorimotor and mobility
❖ Located in the cortex, hypothalamus, internal capsule and brainstem 
Study Design N Baseline Seizure 
frequency
Age
(median)
Seizure Foci 
location
Treatment Control/ 
comparison
Outcome 
Measures
Dwivedi R 
(2017)1
RCT 116 2/ day 9.5 UL, BL, TL, NTL SR MM S Freedom 
QoL
Morrell (2011)2 RCT 191 >3/ month 35 UL, BL, TL, NTL RNS MM S Frequency
QoL
Heck (2014)3 Prospective 
Cohort
175 >3/ month 35 UL, BL, TL, NTL RNS Seizures at 
Baseline
S Frequency
QoL
Engel (2012)4 RCT 37 >2/ week 26 TL SR MM S Freedom
QoL
Jobst (2017)5 Prospective 
Cohort
120 20/ month 34 UL, BL, TL, NTL RNS Seizures at 
Baseline
S Frequency
QoL
Miller (2015)6 Case Study 1 8/ day 38 Motor Cortex RNS s/p SR Seizures at 
baseline
S Frequency
Geller (2017)7 Prospective 
Cohort
111 7.7/ month 37 BL, UL, TL RNS Seizures at 
baseline
S Frequency
QoL
Design Foci Location Treatment Control Outcome
RCT = Randomized clinical trial TL = Temporal lobe, NTL = Non 
temporal lobe, UL = Unilateral, BL = 
Bilateral
SR = Surgical Resection of seizure foci
RNS - Responsive Neurostimulation
RNS s/p SR - RNS placed after surgical 
resection
MM = Medical Management S Freedom = Seizure Freedom
S Frequency = Seizure frequency
QoL = Quality of Life
Study Seizure 
Frequency
Seizure 
Freedom
QoL Endurance of 
Therapy
Severe Adverse 
Events (% of N)
Dwivedi R 
(2017)
S S S A 33%
Morrell 
(2011)
S N/A S I 5.2%
Heck (2014) S N/A S A 7%
Engel (2012) S S S A 43%
Jobst (2017) S N/A S A 11.6%
Miller (2015) S N/A N/A M 0
Geller (2017) S N/A S A 11.7%
Seizure Frequency Seizure Freedom QoL (Quality of Life) 
improvement
Endurance of Therapy Severe Adverse Events 
S = Significant reduction 
compared to control
NS = Not significant reduction 
compared to control
N/A = not applicable 
S = Patients with treatment 
were significantly more likely to 
be free of seizures compared to 
controls
NS = Patients with treatment 
were not significantly more 
likely to be free of seizures 
compared to controls
N/A = not applicable 
S = Significant improvement 
compared to control
NS = Not significant 
improvement compared to 
control
N/A = not applicable 
A  - Significant improvement 
compared to controls for > 12  
months
M - Significant improvement 
compared to controls for > 6 
months
I - Significant improvement 
compared to controls for < 6 
months
N/A - Not measured 
Among the intervention groups 
what was the frequency of 
deaths / permanent physical 
disability / hospitalization longer 
than 1 day
OUTCOMES Surgical Resection Neuropace RNS
Seizure Reduction 
(RCTs)
Not Evaluated Significant improvement vs 
MM (reduced by 41%)
Seizure Elimination 
(RCTs)
Significant improvement vs MM 
(77% Seizure Free)
Not Evaluated
Quality of Life Significant Improvement over 
MM
Significant Improvement 
over MM
Adverse Events 33%-43% 5.2%-11.7%
Inclusion Criteria Exclusion Criteria
Human Research
Adult and child participants
Full text
Case studies, cohort studies, 
randomized clinical trials
Animal Research
Methodological Analysis
Systematic reviews or meta analysis
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